8. Amoebiasis / Entamoeba histolytica - Morphology, life cycle, pathogenesis, lab diagnosis

Reading File
Now let me search the library for comprehensive coverage of Entamoeba histolytica:
Finding Sources
Finding Sources
Excellent results. Let me now read the most comprehensive sources in parallel - the Medical Microbiology textbook, Henry's Lab Methods, and Park's PSM:
Reading File
Reading File
Reading File
Good - now let me get more content: the Jawetz microbiology section, the life cycle details from Park's PSM, and the Henry's lab diagnosis section:
Reading File
Reading File
Reading File
Excellent content. Let me now get more from the Medical Microbiology book (which has the best coverage) and fetch the key microscopy images:
Reading File
Loading Image
Reading File
Now let me get the lab diagnosis section from Medical Microbiology (which had the most comprehensive content) and also a quick look at the Sherris microbiology for the life cycle diagram:
Reading File
Finding Sources
Now let me get the life cycle section from Medical Microbiology and the Sleisenger GI textbook:
Reading File
Reading File
I have the life cycle diagram from Medical Microbiology. Let me fetch it and also get the Henry's lab diagnosis section more completely:
Loading Image
Reading File
I now have comprehensive, rich content from multiple authoritative sources. Let me compile the complete answer:

Amoebiasis / Entamoeba histolytica

Classification

Entamoeba histolytica is a protozoan parasite (Kingdom Protista, phylum Amoebozoa). It is the causative agent of amoebiasis - defined by WHO as "harbouring E. histolytica with or without clinical manifestations." Symptomatic disease occurs in less than 10% of infected individuals.
Important distinction: What was once called "E. histolytica" morphologically actually encompasses four species: pathogenic E. histolytica and non-pathogenic E. dispar, E. moshkovskii, and E. bangladeshi - all morphologically indistinguishable; differentiation requires molecular methods.

1. Morphology

E. histolytica exists in two stages:

A. Trophozoite (Vegetative form)

  • Size: 12-50 µm (invasive forms typically >20 µm; non-pathogenic forms 15-20 µm)
  • Motility: Actively motile by unidirectional pseudopodial movement - a hyaline pseudopod is extended, then the rest of the cell is drawn forward ("snail-like")
  • Cytoplasm: Two zones:
    • Ectoplasm (outer): Clear, hyaline
    • Endoplasm (inner): Granular; may contain ingested red blood cells (pathognomonic - seen only in E. histolytica, never in E. coli or other commensals)
  • Nucleus: Single; nuclear membrane lined by fine, regularly distributed chromatin granules (uniform peripheral chromatin); karyosome (endosome) is small and central
  • Key feature: Erythrophagocytosis (RBCs in cytoplasm) is the only pathognomonic feature in stool specimens

B. Cyst (Infective form)

  • Size: 10-20 µm
  • Shape: Spherical, with a refractile wall
  • Nuclei: 1 (uninucleate, immature) → 2 → 4 nuclei (mature, quadrinucleate - infective stage). Each nucleus has the same fine peripheral chromatin and central karyosome as the trophozoite
  • Chromatoid bars: Cigar-shaped masses of ribonucleoprotein with smooth, rounded ends (this distinguishes from E. coli cysts, which have splintered/frayed chromatoid bars)
  • Glycogen vacuole: Present in early cysts; disappears as maturation progresses
  • Found only in lumen of colon and mushy/formed feces

Comparison: E. histolytica vs. E. coli

FeatureE. histolyticaE. coli
Trophozoite size12-50 µm20-30 µm
Cyst size10-20 µm10-30 µm
Peripheral nuclear chromatinFine, evenly dispersed ringCoarse, clumped
KaryosomeCentral, sharpEccentric, coarse
Ingested RBCsPresent (pathognomonic)Absent
Cyst nuclei1-41-8
Chromatoid barsRounded endsSplintered, frayed ends
(Medical Microbiology 9e, Table 72.1)

Microscopy - trichrome stain (1000x):
Intestinal protozoa trichrome stain - A: E. histolytica/dispar trophozoites; B: E. histolytica/dispar cyst with 3 of 4 nuclei and rounded chromatoid bar; C: Trophozoites with ingested RBCs (arrow); D-E: E. coli trophozoites and cyst; F: C. polecki cyst
(Henry's Clinical Diagnosis, Fig. 65.10 - A: E. histolytica/dispar trophozoites; B: Cyst with 3 of 4 nuclei and rounded chromatoid bar; C: Trophozoites with ingested RBCs - arrow; D-E: E. coli forms; F: C. polecki cyst)

2. Life Cycle

Life cycle of Entamoeba histolytica - showing ingestion of mature cyst, excystation in duodenum, trophozoites in colon, cyst formation, and possible invasion leading to extraintestinal abscesses
(Medical Microbiology 9e, Fig. 72.1 - Life cycle of E. histolytica)
The life cycle involves two stages: trophozoite and cyst. Humans are the only reservoir of infection.

Step-by-step:

  1. Ingestion of mature quadrinucleate cysts - via contaminated food/water (fecal-oral route). Trophozoites cannot survive in the external environment or gastric acid, so cysts are the infective stage.
  2. Excystation - Cysts pass through the stomach; exposure to gastric acid stimulates release of the pathogenic trophozoite in the duodenum. Each quadrinucleate cyst produces 8 trophozoites (4 nuclei → 8 cells by binary fission).
  3. Colonization of large intestine - Trophozoites descend to the large intestine (primarily caecum and ascending colon, then rectosigmoid). They dwell in the colon, multiply by binary fission.
  4. Two possible outcomes:
    • Non-invasive: Trophozoites remain in the lumen → encyst → cysts passed in formed stool → environmental contamination → transmission
    • Invasive: Trophozoites invade the bowel wall → ulceration → may enter portal circulation → liver (most common extraintestinal site), then lungs, brain, heart, skin
  5. Encystment - When conditions become unfavorable (temperature drop, desiccation), trophozoites retract pseudopodia, become spherical, and encyst (uninucleate → quadrinucleate cyst)
  6. Excretion - Cysts excreted in stool; carriers can shed up to 1.5 × 10⁷ cysts/day. Cysts survive in feces, water, and soil for several days at low temperature/moisture.
Cyst survival: Survive in moist conditions for days to weeks; resistant to chlorination at standard water treatment doses; killed by drying, heating to ~55°C, or freezing. Sand filtration and boiling are effective.

3. Pathogenesis

Mechanisms of tissue invasion

After excystation, invasive trophozoites use multiple mechanisms to destroy tissue:
  1. Galactose-inhibitable adherence protein (lectin) - Trophozoites attach to colonic epithelial cells via a Gal/GalNAc-specific lectin on their surface. This attachment is required for cytolysis to occur.
  2. Cytotoxin production - After attachment, trophozoites secrete toxins that cause lytic necrosis (not inflammatory necrosis initially). This causes a lethal alteration in host cell membrane permeability → irreversible rise in intracellular calcium → cell death.
  3. Lysing of immune cells - Trophozoites lyse colonic epithelial cells, neutrophils, lymphocytes, and monocytes. Release of toxic neutrophil constituents after neutrophil lysis amplifies tissue destruction.
  4. Anaerobic preference - Amebae are killed by ambient oxygen concentrations; they thrive in low-oxygen environments (colonic lumen, abscess cavities).

Pathological lesions

Intestinal (colonic) lesions:
  • Initial lesion: Pinhead-sized ulcer with raised edges in the mucosa; mucus, necrotic cells, and amebae exude
  • Trophozoites multiply above the muscularis mucosae, spreading laterally → undermine mucosa
  • Classic "flask-shaped" (collar-button) ulcer: Narrow neck through mucosa leading to an expanded necrotic area in the submucosa - small point of entry, large necrotic base. This is the hallmark lesion of amoebiasis.
  • Bacterial superinfection occurs in larger, established ulcers
  • Coalescence of ulcers → large denuded mucosal areas
  • Ameboma (amoebic granuloma): Granulomatous tumorlike mass on intestinal wall, can obstruct the lumen and mimic carcinoma - produces "napkin ring lesion"
  • Perforation into peritoneal cavity is possible
Extraintestinal spread:
  • Trophozoites penetrate the muscularis, enter mesenteric venules → portal bloodliver
  • Amebic liver abscess (ALA): Most common extraintestinal form (~5% of intestinal cases). Predominantly right lobe, usually single. Aspirate is classically "anchovy sauce" / chocolate-colored pus (liquefied hepatic parenchyma). Trophozoites found at the margin of abscess, not in the center.
  • Hematogenous/contiguous spread → lungs (rupture across diaphragm), brain, pericardium, skin (perianal ulcers)
Factors determining invasion:
  • Number of amebae ingested
  • Pathogenic capacity of the strain (zymodeme)
  • Host immunity and gut motility
  • Enteric bacteria (enhance amebic growth)

4. Laboratory Diagnosis

A. Microscopy (Stool Examination)

  • Gold standard for intestinal amoebiasis
  • Examine at least 3 stool specimens on separate days (parasites not homogeneously distributed)
  • Fresh liquid/semi-liquid stools → look for motile trophozoites (survive only a few hours outside body; must be examined immediately)
  • Formed stools → cysts (more stable)
Wet mount: Direct or concentration methods
  • Trophozoites show rapid, progressive, unidirectional motility via hyaline pseudopodia; sharp ectoplasm-endoplasm demarcation
Permanent stained smear (Trichrome or iron-hematoxylin stain):
  • Best method for detailed morphologic identification
  • Shows nuclear detail: uniform peripheral chromatin + central karyosome
  • Ingested RBCs in trophozoites = pathognomonic for invasive E. histolytica
Concentration techniques (formalin-ethyl acetate): For cyst detection
PAS stain on tissue sections: Trophozoites stain prominently
Note: E. histolytica is morphologically indistinguishable from E. dispar, E. moshkovskii, and E. bangladeshi - RBC ingestion is the only microscopic pathognomonic feature.

B. Culture

  • Robinson's medium / Jones' medium / Boeck-Drbohlav medium
  • Not widely used for diagnosis; mainly for research
  • Useful for zymodeme analysis

C. Antigen Detection (EIA/ELISA)

  • Enzyme immunoassay (EIA) on stool specimens
  • Highly specific; can differentiate E. histolytica from E. dispar
  • Commercially available (e.g., E. histolytica II ELISA, TechLab)
  • Sensitivity ~85-90%, specificity ~99%
  • Preferred over microscopy for species-level diagnosis

D. Serology (Antibody Detection)

  • Detects host anti-amebic IgG antibodies
  • Most useful for extraintestinal amoebiasis (ALA)
  • ~95% of ALA patients are seropositive
  • ~70% seropositive in active intestinal infection
  • ~10% seropositive in asymptomatic carriers
  • Tests: Indirect hemagglutination (IHA) - most sensitive; ELISA; counterimmunoelectrophoresis (CIE); indirect fluorescent antibody (IFA); latex agglutination
  • Limitation: Titers persist months-to-years after treatment, so cannot distinguish current from past infection; less useful in endemic areas

E. Molecular Methods (PCR / DNA probes)

  • Most sensitive and specific method
  • Can definitively distinguish E. histolytica from E. dispar and other species
  • FDA-approved multiplex panels: BioFire FilmArray GI Panel, BD MAX Enteric Parasite Panel, xTag GI Pathogen Panel
  • Useful when serology/antigen tests are inconclusive

F. Aspiration of Liver Abscess

  • Aspirate is chocolate-brown ("anchovy sauce") pus
  • Trophozoites more likely in last aspirated material (at abscess wall margin)
  • Direct microscopy or permanently stained slides
  • PCR amplification of amebic 16S rRNA from aspirate is highly reliable

G. Imaging

  • Ultrasound, CT scan, MRI of liver: Show abscess (usually single, right lobe)
  • Cannot distinguish amebic from pyogenic abscess on imaging alone - requires serology

Summary Table: Lab Diagnosis

TestBest forNotes
Stool microscopy (wet mount + trichrome)Intestinal amoebiasis3 specimens; RBC phagocytosis = pathognomonic
Antigen EIA on stoolIntestinal amoebiasisDifferentiates E. histolytica vs E. dispar
Serology (IHA, ELISA)ALA; extraintestinal disease95% positive in ALA; persists after cure
PCR / molecularSpecies differentiationMost specific; FDA-approved panels
Liver aspirate microscopyALALast aspirated material; margins of abscess
CultureResearch onlyZymodeme analysis

Epidemiology (Quick Review)

  • Worldwide distribution; highest in tropical/subtropical regions with poor sanitation
  • Global: ~50 million infected; ~100,000 deaths/year
  • India: ~15% prevalence (range 3.6-47.4%)
  • Incubation period: 2-4 weeks (can be longer)
  • Transmission: fecal-oral (contaminated water/food), oral-anal sexual contact, mechanical vectors (flies, cockroaches)
  • Cysts resist standard chlorination; sand filtration and boiling are effective

Treatment (Brief)

  • Invasive/systemic disease: Metronidazole or tinidazole (systemic penetration) → followed by luminal agent
  • Luminal agents (to eradicate cysts/asymptomatic carriage): Diloxanide furoate, paromomycin, iodoquinol
  • Treatment of asymptomatic carriers prevents environmental shedding

Sources: Medical Microbiology 9e (Murray); Henry's Clinical Diagnosis 23e; Park's Textbook of Preventive and Social Medicine; Jawetz Medical Microbiology 28e; Sleisenger & Fordtran's GI and Liver Disease; Robbins Pathologic Basis of Disease
This is a shared conversation. Sign in to Orris to start your own chat.